Unicycive Therapeutics (NASDAQ:UNCY) Now Covered by Analysts at B. Riley Financial

B. Riley Financial assumed coverage on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a note issued to investors on Friday. The firm set a “buy” rating and a $22.00 price target on the stock. B. Riley Financial’s price target points to a potential upside of 187.21% from the company’s current price.

Other equities analysts have also issued reports about the company. Guggenheim dropped their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Westpark Capital started coverage on Unicycive Therapeutics in a research report on Thursday, February 19th. They set a “buy” rating for the company. Benchmark decreased their price target on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating on the stock in a research note on Monday, April 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, March 27th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $24.75.

Unicycive Therapeutics Stock Up 7.0%

Shares of UNCY opened at $7.66 on Friday. The business has a 50-day simple moving average of $6.88 and a two-hundred day simple moving average of $6.18. The stock has a market cap of $193.32 million, a price-to-earnings ratio of -3.53 and a beta of 1.81. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $11.00.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.36). On average, equities analysts anticipate that Unicycive Therapeutics will post 1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC bought a new position in Unicycive Therapeutics during the 4th quarter valued at about $5,856,000. Cantor Fitzgerald L. P. purchased a new position in shares of Unicycive Therapeutics during the fourth quarter valued at approximately $1,154,000. Geode Capital Management LLC boosted its position in shares of Unicycive Therapeutics by 36.2% during the fourth quarter. Geode Capital Management LLC now owns 171,290 shares of the company’s stock valued at $989,000 after buying an additional 45,563 shares during the period. Vivo Capital LLC grew its stake in shares of Unicycive Therapeutics by 57.4% during the third quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock valued at $7,804,000 after buying an additional 652,901 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Unicycive Therapeutics in the third quarter worth approximately $512,000. Institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.